The identification of treatment approaches for ovarian cancer patients who are resistant to standard platinum-based chemotherapy is an urgent clinical need.

The Nachtigal laboratory has developed a new drug called a glycosylated antitumor ether lipid (“GAEL”), that can kill chemotherapy-resistant high-grade serous ovarian cancer cells. To bring this promising class of drugs to clinical trials, we need to first understand how they induce cancer cell killing.

With Ovarian Cancer Canada’s investment, the team will perform experiments to examine the mechanism by which a specific GAEL – called L-Rham – kills cancer cells.